Pregabalin for the treatment of fibromyalgia

Expert Opinion on Pharmacotherapy

Volumn 13, Issue 10, 2012, Pages 1527-1533

  Smith, Maree T ^a   Moore, Brendan J ^b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b Axxon Pain Medicine   (Australia)

Author keywords

Adverse events; Fibromyalgia; NNH; NNT; Pain relief; Pharmacokinetics; Pregabalin; Sleep

Indexed keywords

DULOXETINE; MILNACIPRAN; PLACEBO; PREGABALIN; VOLTAGE GATED CALCIUM CHANNEL;

ANALGESIA; ARTICLE; CLINICAL PRACTICE; COMORBIDITY; CONSTIPATION; CREATININE CLEARANCE; DIGESTIVE SYSTEM INFLAMMATION; DIZZINESS; DRUG ABSORPTION; DRUG APPROVAL; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG TOLERABILITY; DRUG WITHDRAWAL; FIBROMYALGIA; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL ABSORPTION; HEADACHE; HEART FAILURE; HUMAN; LIVER FAILURE; META ANALYSIS (TOPIC); NAUSEA; NONHUMAN; PERIPHERAL EDEMA; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; SIDE EFFECT; SLEEP; SOMNOLENCE; SUICIDE; SYSTEMATIC REVIEW (TOPIC); THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; WEIGHT GAIN;

ANALGESICS; FIBROMYALGIA; GAMMA-AMINOBUTYRIC ACID; HUMANS; SEROTONIN UPTAKE INHIBITORS;

EID: 84863083785     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2012.687373     Document Type: Article

References (35)

1. McNalley JD, Matheson DA, Bakowshy VS. the epidemiology of self-reported fibromyalgia in Canada. Chronic Dis Can 2006;27:9-16
2. McBeth J, Mulvey MR. Fibromyalgia: Mechanisms and potential impact of the ACR2010 classification criteria. Nat Rev Rheumatol 2012;8:108-16
3. Fitzcharles M-A, Yunus MB. the clinical concept of fibromyalgia as a changing paradigm in the past 20 years. Pain Res Treat 2012;2012:8
4. White KP, Harth M. Classification, epidemiology and natural history of fibromyalgia. Curr Pain Headache Rep 2001;5:320-9
5. Wolfe F, Smythe HA, Muhammad B, et al. the American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum 1990;33:160-72
6. Wolfe F, Clauw DJ, Fitzcharles M-A, et al. the American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res (Hoboken) 2010;62:600-10
7. McCarberg B, Barkin RL, Wright JA, et al. Tender points as predictors of distress and the pharmacologic management of fibromyalgia syndrome. Am J Ther 2003; 10:176-92
8. Smith HS, Harris R, Clauw D. Fibromyalgia: An afferent processing disorder leading to a complex pain generalized syndrome. Pain Physician 2011;14:E217-45
9. Sarchielli P, Di Filippo M, Nardi K, Calabresi P. Sensitization, glutamate, and the link between migraine and fibromyalgia. Curr Pain Headache Rep 2007;11:343-51
10. Russell IJ, Vaeroy H, Javors M, Nyberg F. Cerebrospinal fluid biogenic amine metabolites in fibromyalgia/fibrositis syndrome and rheumatoid arthritis. Arthritis Rheum 1992;35:550-6
11. Mease PJ, Dundon K, Sarzi-Puttini P. Pharmacotherapy of fibromyalgia. Best Pract Res Clin Rhematol 2011;25:285-97
12. Li Z, Taylor CP, Weber M, et al. Pregabalin is a potent and selective ligand for (2)-1 and (2)-2 calcium channel subunits. Eur J Pharmacol 2011;667:80-90
13. Shoji S, Suzuki M, Tomono Y, et al. Population pharmacokinetics of pregabalin in healthy subjects and patients with post-herpetic neuralgia or diabetic peripheral neuropathy. Br J Clin Pharmacol 2011;72:63-76
14. Smith HS, Barkin RL. Fibromyalgia syndrome: A discussion of the syndrome and pharmacotherapy. Am J Ther 2010;17:418-39
15. Randinitis EJ, Posvar EL, Alvey CW, et al. Pharmacokinetics of pregabalin in subjects with various degrees of renal function. Clin Pharmacol 2003;43:277-83
16. Crofford LJ, Rowbotham M, Mease PJ, et al. Pregablin 1008-105 Study Group. Pregabalin for the treatment of fibromyalgia syndrome: Results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2005;52:1264-73
17. Arnold LM, Russell IJ, Diri EW, et al. A 14-week, randomized, double-blinded, placebo-controlled monotherapy trial of pregabalin in patients with fibromyalgia. J Pain 2008;9:792-805
18. Mease PJ, Russell IJ, Arnold LM, et al. A randomized, double-blind, placebo-controlled, phase III trial of pregabalin in the treatment of patients with fibromyalgia. J Rheumatol 2008;5:502-14
19. Pauer L, Winkelmann A, Arsenault P, et al. A0081100 Investigators. An international, randomized, double-blind, placebo-controlled, phase III trial of pregabalin monotherapy in treatment of patients with fibromyalgia. J Rheumatol 2011;38:2643-2
20. Crofford LJ, Mease PJ, Simpson SL, et al. Fibromyalgia relapse evaluation and efficacy for durability of meaningful relief (FREEDOM): A 6-month, double-blind, placebo-controlled trial with pregabalin. Pain 2008;136:419-31
21. Hauser W, Bernardy K, Uceyler N, Sommer C. Treatment of fibromyalgia syndrome with gabapentin and pregabalin - a meta-analysis of randomized controlled trials. Pain 2009;145:69-81
22. Hauser W, Petzke F, Sommer C. Comparative efficacy and harms of duloxetine, milnacipran, and pregabalin in fibromyalgia syndrome. J Pain 2010;11:505-21
23. Tzellos TG, Toulis KA, Goulis DG, et al. Gabapentin and pregabalin in the treatment of fibromyalgia: A systematic review and a meta-analysis. J Clin Pharm Ther 2010;35:639-56
24. Straube S, Derry S, Moore RA, McQuay HJ. Pregabalin in fibromyalgia: Meta-analysis of efficacy and safety from company clinical trial reports. Rhematology (Oxford) 2010a;49:706-15
25. Straube S, Derry S, Moore RA, et al. Pregabalin in fibromyalgia - responder analysis from individual patient data. BMC Musculoskelet Disord 2010b;11:150
26. Choy E, Marshall D, Gabriel ZL, et al. A systematic review and mixed treatment comparison of the efficacy of pharmacological treatments for fibromyalgia. Semin Arthritis Rheum 2011;41:335-45
27. Siler AC, Gardner H, Yanit K, et al. Systematic review of the comparative effectiveness of antiepileptic drugs for fibromyalgia. J Pain 2011;12:407-15
28. Sackett DL, Straus SE, Richardson WS, et al. Evidence-based medicine: how to practice and teach EBM. JAMA 2000;284:2382-3
29. Roth T, Lankford DA, Bhadra P, et al. Effect of pregabalin on sleep in patients with fibromyalgia and sleep maintenance disturbance: A randomized, placebo-controlled, 2-way crossover polysomnography study. Arthritis Care Res (Hoboken) 2012; [Epub ahead of print]
30. Zaccara G, Gangemi P, Perucca P, Specchio L. the adverse event profile of pregabalin: A systematic review and meta-analysis of randomized controlled trials. Epilepsia 2011;52:826-36
31. Drug Enforcement Administration, Department of Justice. Schedules of controlled substances: placement of pregabalin into schedule V. Final rule. Fed Regist 2005; 70(144):43633-5
32. Vaishnavi SN, Nemeroff CB, Plott SJ, et al. Milnacipran: A comparative analysis of human monoamine uptake and transporter binding affinity. Biol Psychiatry 2004; 55:320-2
33. Farmer MV, Trugman JM, Wang Y, Gendreau RM. Effect of adding milnacipran to pregabalin for managing fibromyalgia: A randomized, open-label, controlled study [abstract]. Arthritis Rheum 2010; 62(Suppl 10):648
34. Busch AJ, Schachter CL, Overend TJ, et al. Exercise for fibromyalgia: A systematic review. J Rheumatol 2008;35:1130-44
35. Carville SF, Arendt-Nielsen S, Bliddal H, et al. EULAR evidence-based recommendations for the management of fibromyalgia syndrome. Ann Rheum Dis 2008;67:536-41